A Reversal for Nanovibronix Inc (NASDAQ:NAOV) Is Near. The Stock Has Decrease in Shorts

NanoVibronix, Inc. (NASDAQ:NAOV) Logo

The stock of Nanovibronix Inc (NASDAQ:NAOV) registered a decrease of 7.2% in short interest. NAOV’s total short interest was 11,600 shares in January as published by FINRA. Its down 7.2% from 12,500 shares, reported previously. With 2,900 shares average volume, it will take short sellers 4 days to cover their NAOV’s short positions.

It closed at $3.35 lastly. It is up 0.00% since January 24, 2018 and is . It has by 0.00% the S&P500.

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target wound healing and pain therapy. The company has market cap of $21.83 million. The Company’s products include WoundShield, a patch therapeutic ultrasound device, which facilitates tissue regeneration and wound healing; PainShield, a disposable patch therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and UroShield, an ultrasound product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It currently has negative earnings. The firm sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements.

More notable recent NanoVibronix, Inc. (NASDAQ:NAOV) news were published by: Nasdaq.com which released: “Amazon Witnesses Robust Holiday Performance With Strong Sales – Nasdaq” on December 28, 2018, also Nasdaq.com with their article: “C$ hits 2-week low as some economists see Nov GDP decline – Nasdaq” published on January 23, 2019, Nasdaq.com published: “Holiday Sales Strongest in Six Years: ETFs Set to Surge – Nasdaq” on December 26, 2018. More interesting news about NanoVibronix, Inc. (NASDAQ:NAOV) were released by: Nasdaq.com and their article: “Australia shoppers boost Nov retail sales to 5-month highs – Nasdaq” published on January 10, 2019 as well as Nasdaq.com‘s news article titled: “Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain – Nasdaq” with publication date: January 23, 2019.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *